期刊
RENAL FAILURE
卷 45, 期 1, 页码 -出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/0886022X.2023.2199093
关键词
Roxadustat; erythropoietin; thyroid dysfunction; renal anemia
This cohort study aimed to investigate the effects of roxadustat and erythropoietin on thyroid function in patients with renal anemia. The results showed that roxadustat group had significantly lower levels of TSH, FT3, and FT4 compared to the erythropoietin group. Roxadustat was found to be an independent influencing factor for thyroid dysfunction.
Purpose: This cohort study was designed to explore whether roxadustat or erythropoietin could affect thyroid function in patients with renal anemia.Methods: The study involved 110 patients with renal anemia. Thyroid profile and baseline investigations were carried out for each patient. The patients were divided into two groups: 60 patients taking erythropoietin served as the control group (rHuEPO group) and 50 patients using roxadustat served as the experimental group (roxadustat group).Results: The results indicated that there were no significant differences in serum total thyroxine (TT4), total triiodothyronine (TT3), free triiodothyronine (FT3), free thyroxine (FT4) or thyroid stimulating hormone (TSH) between the two groups at baseline. After treatment, TSH, FT3, and FT4 were significantly lower in the roxadustat group than in the rHuEPO group (p < 0.05). After adjusting for age, sex, dialysis modality, thyroid nodules and causes of kidney disease, Cox regression showed that roxadustat was an independent influencing factor on thyroid dysfunction (HR 3.37; 95% CI 1.94-5.87; p < 0.001). After 12 months of follow-up, the incidence of thyroid dysfunction was higher in the roxadustat group than in the rHuEPO group (log-rank p < 0.001).Conclusion: Roxadustat may lead to a higher risk of thyroid dysfunction, including low TSH, FT3 and FT4, than rHuEPO in patients with renal anemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据